|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| 最高研发阶段批准上市 | 
|  | 
| 首次获批日期2012-01-27 | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| 最高研发阶段批准上市 | 
|  | 
| 首次获批日期2006-01-26 | 
|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| 最高研发阶段批准上市 | 
|  | 
| 首次获批日期1983-11-14 | 
A Multicenter, Active Control, Parallel Group, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops in Patients With Dry Eye Disease
This study is planned to Evaluate the Efficacy and Safety of SCAI-001 Eye Drops(Cyclosporine 0.01%, 0.02%) compared to Restasis(Cyclosporine 0.05%) in Patients with Dry Eye Disease.
100 项与 SCAI Therapeutics Co., Ltd. 相关的临床结果
0  项与 SCAI Therapeutics Co., Ltd. 相关的专利(医药)
100 项与 SCAI Therapeutics Co., Ltd. 相关的药物交易
100 项与 SCAI Therapeutics Co., Ltd. 相关的转化医学